Conclusion
Achievements in medicinal chemistry and pharmacology in studying the mechanisms of action of antiaggregants provide a deeper insight into the physicochemical backgrounds of phenomena involved in thrombocyte aggregation and provide controls for these processes using inductors and inhibitors of aggregation.
The information gained from experiments indicates the promising directions in the search for new, more efficient antithrombotic drugs. Good prospects are also related to the synthesis and search for inhibitors of various anzymes controlling the energetics of thrombocytes and capable of affecting their functional activity.
At present, a number of compounds capable of inhibiting the reactions of serotonin, fibrinogen, and thrombin, and combinations of serotonin and thromboxan inhibitors, are in various stages of characterization and implementation into practice.
Similar content being viewed by others
References
M. A. Packman,Thromb. Haemostasis,50, 610–619 (1983).
S. Sherry,J. Int. Med. Res.,229, 111–116 (1991).
M. D. Mashkovskii,Drugs [in Russian], Part II, Meditsina, Moscow (1993).
v. A. Makarov,Farmakol. Toksikol.,52(4), 9–13 (1989).
I. N. Bokarev,Ter. Arkhiv,64(10), 101–105 (1992).
J. R. O'Brien,Lancet,1, 779–782 (1968).
M. B. Zucker and J. Peterson,Proc. Soc. Exp. Biol. Med.,127, 547–551 (1968).
B. Loucka,Sci. Pharm.,37(9), 416–420 (1988).
J. A. G. Reilly and G. A. Fitzgerald,Drugs,35, 154–176 (1988).
J. Webster and A. S. Douglas,Blood Rev.,1(1), 9–20 (1987).
J. Vane,Monthly Nature,367, 215–216 (1994).
D. Sciftede, A. Klee, K. Meithimann,Abstracts of the 3rd Erfurt Workshop on Platelets, Erfurt (1989), Abstr. 44.
J. J. Thebault, J. Chick, and H. Caplain,Abstracts of the 3rd International Conference on Drug Absorption, Edinburgh (1988), Abstr. 98.
T. Meade,Am. J. Cardiol.,65(6), 7–11 (1990).
French Patent No. 8903138;Chem. Abstr., 902 (1990).
N. Desideri, I. Sestili, P. Piccardoni, et al.,Arch. Pharm.,325(12), 773–777 (1992).
F. Doranden,Lyon Pharm.,42(2), 137–147 (1991).
F. Vaghi, M. Colombo, L. Pierucci, et al.,Drug. Exp. Clin. Res., No. 6, 249–260 (1993).
V. Coto, T. Picano, M. Cocorra, et al.,Rass. Med. Sper.,38(11–12), 237–243 (1991).
E. Ohshima, H. Takami, H. Harakawa, et al.,J. Med. Chem.,36(3), 417–420 (1993).
Sh. S. Bradwat, C. Cude, D. S. Cohen, et al.,J. Med. Chem.,36, 205–209 (1993).
K. M. Lakin, V. A. Makarov, N. V. Novikova, et al.,Farmakol. Toksikol.,46(3), 113–125 (1983).
N. Kieffer and D. R. Philips,Ann. Rev. Cell. Biol.,6, 329–357 (1990).
P. C. Zamecnik, J. M. G. Kim, G. Taylor, et al.,Proc. Nat. Acad. Sci. USA,89(6), 2370–2373 (1992).
I. S. Severina,Byull. Eksp. Biol. Med.,3, 230–235 (1995).
T. W. Ku, W. H. Miller, W. E. Bondinelli, et al.,J. Med. Chem.,35, 2040–2048 (1992).
P. L. Barker, S. Bullens, S. Bunting, et al.,J. Med. Chem.,38, 9–12 (1995).
H. K. Gold, B. S. Collar, T. Jasuda, et al.,Circulation,77, 670–677 (1988).
M. Pfaff, M. A. McLane, L. Beviglia, et al.,Cell. Adhes. Commun.,2, 491–501 (1994).
M. A. McLane, M. A. Kowalska, L. Silver, et al.,Biochem. J.,301, 429–436 (1994).
J. Williams, B. Rucinski, J. C. Holl, et al.,Biochem. Biophys. Acta,1039, 81–89 (1990).
M. Gurrath, G. Muller, H. Kessler, et al.,Eur. J. Biochem.,210, 911–921 (1992).
US Patent No. 4857509;Ref. Zh. VNIIPI, Izobret. Stran Mira, No. 15(11), (1990).
E. P. Plow and M. H. Ginsberg,Cell. Adhes.,9, 117–156 (1989).
S. A. Andronati, V. M. Kabanov, T. L. Karaseva, et al.,Proceedings of the 23rd European Peptide Symposium, Peptides, ESCOM, (1994), p. 382.
J. A. Zablocki, J. G. Rico, R. B. Garland, et al.,J. Med. Chem.,38(13), 2378–2393 (1995).
M. Camini and L. Evangelisti,Minerva Med.,83(9), 525–528 (1992).
A. I. Soloview and P. Braquet,Int. Union Physiol. Sci.,7, 166–171 (1992).
S. D. Shukla (ed.),Platelet Activating Factor Receptor: Signal Mechanisms in Molecular Biology, CRS Press, (1993), p. 84.
J. J. Godfroid, G. Dive, J. Lamotte-Brasseer, et al.,Lipids,26(12), 1161–1166 (1991).
J. Casals-Strenzel,Lipids,26(12), 1157–1167 (1991).
J. Casals-Strenzel,Naunyn-Schmiedeberg's Arch. Pharmacol.,335(3), 351–355 (1987).
US Patent No. 4910194;Ref. Zh. Kghim., 5O69P (1991).
C. M. Chesney, D. D. Pifer, L. M. Cagen,Biochem. Biophys. Res. Commun.,144(1), 359–366 (1987).
Jpn. Patent No. 5017997;Ref. Zh. Khim., 11O175P (1987).
FRG Patent No. 2732931;Ref. Zh. Khim., 24O136P (1979).
US Patent No. 4934240;Ref. Zh. Khim., 10O89P (1992).
Jpn. Patent No. 5543476;Ref. Zh. Khim., 15O138P (1981).
J. Casals-Strenzel, G. Muacevic, and K. Weber,Naunyn-Schmiedeberg's Arch. Pharmacol.,334, 44–48 (1986).
M. A. Sablina, I. P. Ushakova, G. A. Serebinnikova,Khim.-Farm. Zh.,28(6), 9–24 (1994).
M. Prosdocini, M. Finesso, and E. Dejana,Pharmacol. Res. Commun.,20(1), 1–6 (1988).
É. S. Gabrielyan, S. É. Akopov, and M. R. Grigoryan,Abstracts of Papers. The 6th All-Union Meeting of Pharmacologists [in Russian], Tashkent (1988), p. 76.
C. N. Berry and A. Choppin,Br. J. Pharmacol.,105(Suppl.), 50 (1992).
S. A. Andronati, T. L. Karaseva, V. I. Pawlovsky, et al.,Pharmazie,50(9), 632–634 (1995).
O. V. Demina, P. V. Vrzhets, A. A. Khodonov, et al.,Bioorg. Khim.,21(12), 933–940 (1995).
N. A. Meanwell, P. Hewawasam, J. A. Thomas, et al.,J. Med. Chem.,36, 3251–3264 (1993).
Author information
Authors and Affiliations
Additional information
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 31, No. 3, pp. 3–9, March, 1997.
Rights and permissions
About this article
Cite this article
Andronati, S.A., Karaseva, T.L. Achievements and prospects in the creation of antiaggregative drugs (Review). Pharm Chem J 31, 109–115 (1997). https://doi.org/10.1007/BF02464660
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02464660